AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1675865
Drug: Pamidronate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate treatment (n = 76)
Trial: 6347278
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + cyclophosphamide (C) for 12 monthly cycles
Trial: 6347278
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + cyclophosphamide/methotrexate/5‐fluorouracil (CMF) for 12 monthly cycles
Trial: 19328435
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg b.i.d. celecoxib (Celebrex, Pfizer)
Trial: 19328435
Drug: 220 mg
RxNorm normalized name: urea 220 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg b.i.d. naproxen sodium (Aleve, Bayer)
Trial: 6367553
Drug: Verapamil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (10 mg)
Trial: 28820468
Drug: Resveratrol 19.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 19.8 mg with Pegylated-Interferon-α2b and Ribavirin
Trial: 19496898
Drug: Twice-daily application
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily application of 0.1% tacrolimus
Trial: 16330464
Drug: Combined antiplatelet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiplatelet plus moderate intensity anticoagulant therapy
Trial: 12627304
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and endurance training (SE)
Trial: 6712367
Drug: Spironolactone therapy
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone therapy for two to four months
Trial: 6712367
Drug: Chlorthalidone treatment
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone treatment
Trial: 27923550
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg I.V. every 2 weeks for up to 1 year
Trial: 27923550
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 I.V. on days 1, 8, 29, and 36
Trial: 25916335
Drug: Proprietary nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary nutritional supplement containing magnesium, riboflavin and Q10
Trial: 19282313
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control (beta blockers and/or digoxin to reduce heart rate to <80 bpm at rest and <110 bpm after walking)
Trial: 15484727
Drug: Rapeseed meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed meal diet (200 g/kg)
Trial: 28270229
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg every 4 months for five doses)
Trial: 21566547
Drug: Skin protection
RxNorm normalized name: NeutrapHor 1% Skin Protection Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin protection cream containing glycerol, vaseline, and liquid paraffin, applied twice a day
Trial: 21566547
Drug: Vaseline ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaseline ointment, applied twice a day
Trial: 16513607
Drug: Dynamic 18F‐FET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic 18F‐FET PET studies (0‐40 min after injection of 180 MBq of 18F‐FET)
Trial: 15351769
Drug: Topiramate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (25 mg/d to 300 mg/d)
Trial: 8229497
Drug: Chlorpromazine plus
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine plus lorazepam (30 mg/m2 chlorpromazine and 0.04 mg/kg lorazepam, both given intravenously)
Trial: 21464363
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol dose (0.4 g/kg)
Trial: 30946883
Drug: High alcohol
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High alcohol dose (0.6 g/kg)
Trial: 17719311
Drug: Beta-blockers (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (maximal tolerated doses)
Trial: 10340913
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg/day, administered for 21 days)
Trial: 29171468
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day (Group 1)
Trial: 29171468
Drug: Gliclazide MB
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MB 60 mg/day (Group 2)
Trial: 25948124
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus yangxinkang tablets for 4 weeks
Trial: 25948124
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western treatment (Control)
Trial: 14585880
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (800 microg)
Trial: 6724715
Drug: Cimetidine (histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (histamine H2-receptor blocker)
Trial: 24052362
Drug: Ivabradine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (15 mg)
Trial: 29982532
Drug: fractional-dose IPV
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fractional-dose IPV (fIPV)
Trial: 15696331
Drug: BCAA/TRP mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA/TRP mixture (60 g BCAA and 2 g TRP)
Trial: 7933535
Drug: Antibiotic plus
RxNorm normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic plus fluconazole therapy (FLCZ group)
Trial: 7933535
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy only (antibiotic group)
Trial: 9952150
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.5 mg
Trial: 24252674
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate (500 ml administered 2-3 hours before anesthesia)
Trial: 24252674
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (500 ml administered 2-3 hours before anesthesia)
Trial: 10568558
Drug: Pacemaker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker therapy
Trial: 12685882
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 2 weeks
Trial: 12685882
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 4 weeks
Trial: 10574419
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg/HCTZ 12.5 mg
Trial: 18633426
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/HCTZ 12.5 mg
Trial: 8908379
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg twice daily (b.i.d.)
Trial: 8908379
Drug: Glimepiride 16
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride 16 mg once daily (q.d.)
Trial: 8908379
Drug: Glimepiride 8
RxNorm normalized name: glimepiride 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 8 mg twice daily (b.i.d.)
Trial: 6135720
Drug: Estazolam 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 2.0 mg
Trial: 17293731
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg twice daily
Trial: 24926075
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy plus acupuncture for 3 months
Trial: 24926075
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination therapy
Trial: 19639415
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel (60, 90 or 120 mg)
Trial: 15975126
Drug: Stabilization splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilization splint therapy (Group I)
Trial: 12689686
Drug: Ibandronate 2.5
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2.5 mg taken 30 minutes before breakfast
Trial: 8528172
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow examination 2 weeks post-infusion
Trial: 25276626
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation along with regular medicine
Trial: 21316541
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of nevirapine 200-mg tablet
Trial: 12442030
Drug: rG-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rG-CSF (5 microg/kg/dose i.v. twice a day)
Trial: 12442030
Drug: rhuGM-CSF (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuGM-CSF (4 microg/kg/dose i.v. twice a day)
Trial: 31336101
Drug: tablet gaming
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet gaming control
Trial: 28532408
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) administered at 2 days and 1 year postoperatively
Trial: 23392737
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin treatment
Trial: 11421880
Drug: Omeprazole group
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole group (20 mg b.d. for 7 days + 14 days additional therapy with omeprazole 20 mg)
Trial: 11421880
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (7 days triple therapy + placebo for 14 days)
Trial: 9137798
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 160 mg/day
Trial: 7970504
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 800 mg/day
Trial: 7970505
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 1280 mg/day
Trial: 11019429
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg (three times a day)
Trial: 23134097
Drug: Post-discharge warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge warfarin management service with pharmacist education during two or three home visits.
Trial: 10191137
Drug: Melatonin 2.5
RxNorm normalized name: melatonin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2.5 mg
Trial: 8564107
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1.5 mg inhaled daily for 8 weeks
Trial: 3537268
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline sulfate (0.25 mg) administered to 43/85 (50.5%) of ECV candidates
Trial: 20865240
Drug: Sulodexide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (200 mg/day)
Trial: 18000175
Drug: Risk score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk score additionally dependent on a decreased first‐phase insulin response variable from intravenous glucose tolerance tests (IVGTTs)
Trial: 21498906
Drug: Atorvastatin (10mg/day)
RxNorm normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10mg/day)
Trial: 21376564
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil patient-controlled analgesia
Trial: 10799352
Drug: Kamillosan(R) cream
RxNorm normalized name: pantolactone, (R)-
DrugBank: Levomenol (DB13153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kamillosan(R) cream
Trial: 8582464
Drug: 0.5% hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hydrocortisone cream
Trial: 11369904
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (placebo)
Trial: 9277559
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (1,800 mg/day)
Trial: 9277559
Drug: Control calcium
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control calcium intake (800 mg/day)
Trial: 26469356
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus casei Shirota (LcS), administered twice daily for 8 weeks
Trial: 20348164
Drug: Modified tandem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified tandem traction bow appliance (modified TTBA) - Early treatment group
Trial: 20348164
Drug: Modified tandem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified tandem traction bow appliance (modified TTBA) - Late treatment group
Trial: 20348164
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (observed without treatment for 8 months)
Trial: 11778530
Drug: Local chemotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local chemotherapy by fibrobronchoscopy with carboplatin 300 mg combined with intravenous chemotherapy (carboplatin and etoposide regimen)
Trial: 11778530
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy with routine carboplatin and etoposide regimen
Trial: 7056070
Drug: Drionic device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drionic device treatment for hyperhidrosis
Trial: 29087231
Drug: SHP465 mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 mixed amphetamine salts (25 mg)
Trial: 22123358
Drug: Tolvaptan (TLV)
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan (TLV) 30 mg
Trial: 22123358
Drug: Furosemide (FURO)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (FURO) 80 mg
Trial: 22123358
Drug: Tolvaptan (TLV)
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan (TLV) 30 mg and Furosemide (FURO) 80 mg
Trial: 14967419
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard-of-care oral hygiene (SOC)
Trial: 14967419
Drug: Standard-of-care oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care oral hygiene (SOC) alone
Trial: 23703604
Drug: Medication self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication self-management education program (5 sessions including verbal education, 1:1 consultation, practice in medication self-management, and discussion)
Trial: 21726257
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg/day) plus aspirin (100 mg/day)
Trial: 21726257
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg/day) plus clopidogrel (75 mg/day)
Trial: 16393593
Drug: 595 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595 nm cryogen‐cooled pulsed dye laser treatment
Trial: 15459593
Drug: Diltiazem ER
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem ER tablets (240 mg titrated to 360 mg and to 540 mg)
Trial: 15459593
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg titrated to 10 mg and to 20 mg)
Trial: 15459593
Drug: Diltiazem ER
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem ER tablets
Trial: 8354536
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) + Propantheline bromide (15 mg) at bedtime
Trial: 8354536
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg) at bedtime
Trial: 28678033
Drug: Myofascial Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial Release Therapy (MRT)
Trial: 30025540
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT)
Trial: 24994700
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (n = 34): Chest tubes removed if daily drainage ≤250 ml, regardless of protein content.
Trial: 24994700
Drug: Group S:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S: Patients with high protein content preventing removal despite acceptable volume of daily drainage.
Trial: 23232895
Drug: Acetazolamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (750 mg/d) + autoCPAP
Trial: 20694273
Drug: Warfarin (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted to a target INR of 2.0-3.0)
Trial: 20694273
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg bid
Trial: 20694273
Drug: Edoxaban (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (both 30 and 60 mg qd)
Trial: 20694273
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg bid
Trial: 18245547
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine
Trial: 10986213
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg
Trial: 9103749
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) American Lung Association quit program plus nicotine anonymous meetings (n = 70)
Trial: 8250305
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of famotidine (HS)/20 mg of famotidine (AM)
Trial: 8250305
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of famotidine (HS)/placebo (AM)
Trial: 8250305
Drug: Placebo (HS)/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (HS)/20 mg of famotidine (AM)
Trial: 8250305
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of famotidine (HS)/40 mg of famotidine (AM)
Trial: 8250305
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of famotidine (HS)/placebo (AM)
Trial: 8250305
Drug: Placebo (HS)/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (HS)/40 mg of famotidine (AM)
Trial: 24880672
Drug: Phonosurgery/voice therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonosurgery/voice therapy
Trial: 20356558
Drug: 4.5% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5% NaCl solution
Trial: 20356558
Drug: 6% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% NaCl solution
Trial: 20356558
Drug: 7.5% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% NaCl solution
Trial: 27319812
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution (control group)
Trial: 19029562
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine plus midazolam (1 mg/kg ketamine + 0.1 mg/kg midazolam; IVKM)
Trial: 19029562
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine only (1 mg/kg; IVK)
Trial: 12873948
Drug: Tramadol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol plus placebo (100 mg tramadol IM)
Trial: 6138055
Drug: Alcohol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.7 g/kg body weight)